Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists

Gene Therapy and Molecular Biology

Volumn 12, Issue 2, 2008, Pages 253-258

  Martin, Frances M ^a   Harris, Andrew M ^a   Rowland, Randall G ^a   Conner, William ^a   Lane, Matthew ^b   Durbin, Erik ^c   Baron, Andre T ^c,d   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

Author keywords

1 adrenoceptor antagonists; Apoptosis; Bladder cancer; Prevention

Indexed keywords

EID: 77649138555     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Benning CM, Kyprianou N (2002) Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res 62, 597-602.
2. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87, 1603-1612.
3. Caine M (1990) α-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 17, 641-649.
4. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ, Abrams P (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74, 50-56.
5. Chiang CF, Son EL, Wu GJ (2005) Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. Prostate 64, 408-418.
6. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N (1999) α1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161, 2002-2008.
7. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
8. Garrison JB, Kyprianou N (2004) Novel targeting of apoptosis pathways for prostate cancer therapy. Curr Cancer Drug Targets 4, 85-95.
9. Garrison JB, Kyprianou N (2006) Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptormediated pathway. Cancer Res 66:464-472.
10. Garrison JB, Shaw YJ, Chen CS, Kyprianou N (2007) Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res 67, 11344-11352.
11. Grossmann J (2002) Molecular mechanisms of "detachmentinduced apoptosis--Anoikis". Apoptosis 7, 247-260.
12. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT, Kyprianou N (2007) Effect of α1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178, 2176-2180.
13. Hu ZW, Shi XY, Hoffman BB (1998) Doxazosin inhibits proliferation and migration of human vascular smoothmuscle cells independent of α1-adrenergic receptor antagonism. J Cardiovasc Pharmacol 31, 833-839.
14. Hussain SA, James ND (2003) The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 4, 489-497.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57, 43-66.
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
17. Keledjian K, Kyprianou N (2003) Anoikis induction by quinazoline based α1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol 169, 1150-1156.
18. Keledjian K, Garrison JB, Kyprianou N (2005) Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 94, 374-388.
19. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013-2026.
20. Kintscher U, Kon D, Wakino S, Goetze S, Graf K, Fleck E, Hsueh WA, Law RE (2001) Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes. J Cardiovasc Pharmacol 37, 532-539.
21. Kintscher U, Wakino S, Kim S, Jackson SM, Fleck E, Hsueh WA, Law RE (2000) Doxazosin inhibits retinoblastoma protein phosphorylation and G(1)-->S transition in human coronary smooth muscle cells. Arterioscler Thromb Vasc Biol 20, 1216-1224.
22. Kyprianou N (2003) Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 169, 1520-1525.
23. Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60, 4550-4555.
24. Kyprianou N, Jacobs SC (2000) Induction of apoptosis in the prostate by α1-adrenoceptor antagonists: a novel effect of "old" drugs. Curr Urol Rep 1, 89-96.
25. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC (1998) Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159, 1810-1815.
26. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148, 1467-1474.
27. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349, 2387-2398.
28. Pan SL, Guh JH, Huang YW, Chern JW, Chou JY, Teng CM (2000) Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 169, 724-729.
29. Reed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17, 2941-2953.
30. Shaw YJ, Yang YT, Garrison JB, Kyprianou N, Chen CS (2004) Pharmacological exploitation of the α1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem 47, 4453-4462.
31. Streeter EH, Harris AL (2002) Angiogenesis in bladder cancer--prognostic marker and target for future therapy. Surg Oncol 11, 85-100.
32. Tahmatzopoulos A, Lagrange CA, Zeng L, Mitchell BL, Conner WT, Kyprianou N (2005) Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology 65, 1019-1023.
33. Walden PD, Durkin MM, Lepor H, Wetzel JM, Gluchowski C, Gustafson EL (1997) Localization of mRNA and receptor binding sites for the α1-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 157, 1032-1038.
34. Wolf BB, Green DR (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274, 20049-20052.